KR20220104854A - Sport lotion composition comprising neurotransmitter regulating peptide - Google Patents

Abstract

The present invention relates to a composition for sports, musculoskeletal disease management, prevention and treatment of muscle pain, muscle pain relief, body shape correction or cosmetic correction through muscle reduction for the purpose of muscle relaxation by applying peptides and derivatives of peptides that control the release of neurotransmitters and receptors of neurotransmitters to the skin. In the present invention, peptides and derivatives of peptides that regulate the release of neurotransmitters and regulate neurotransmitter receptors used for wrinkle alleviation can be used as an active component of functional cosmetics for cosmetic correction and pharmaceutical compositions for skin external preparations through sports for the purpose of muscle relaxation, musculoskeletal disease management, prevention and treatment of muscle pain, muscle pain relief, body shape correction or muscle reduction.

Description

Sports lotion composition comprising neurotransmitter regulating peptide

The present invention relates to a sports lotion composition comprising a peptide that modulates neurotransmitters. Specifically, management of sports and musculoskeletal disorders containing peptides that control neurotransmitters as active ingredients; body shape correction; Or it relates to a composition for cosmetic correction through muscle loss.

One of the main causes of muscle pain is overuse and muscle imbalance. This is due to incorrect posture or movement to compensate for it. In the modern society where occupations are segmented and specialized, many people have to maintain repetitive motions or fixed postures for a long time. Overuse of muscles due to professional athletes or excessive sports activity results in muscle imbalance. Prolonged contraction of muscles or overuse of muscles can cause muscle pain and deformity of body shape.

The mechanism of muscle contraction begins with the release of neurotransmitters. This proceeds by forming a passage between the two boundaries after the synaptic vesicle and the presynaptic membrane located at the nerve end containing the neurotransmitter are fused. SNARE proteins are three types of protein complexes, and are involved in the fusion of the synaptic vesicle with the presynaptic membrane. The three types of proteins are vesicle protein synaptobrevin (VAMP), plasma membrane binding protein syntaxin 1a, and SNAP-25. The opening of the neurotransmitter release pathway by membrane fusion between the synaptic vesicle and the presynaptic membrane is specifically, t-, a complex of two proteins composed of the syntaxin 1a protein and the SNAP-25 protein attached to the target membrane. It is a result of the interaction of the SNARE and v-SNARE attached to the vesicle.

When the synaptic vesicle and the presynaptic membrane fuse, rearrangement of the lipid bi-layer occurs. Biofilms fundamentally strongly repel each other due to their physicochemical properties. In order to fuse them, a force stronger than this repulsive force must be applied. It is known that the SNARE protein provides this external force. The formation of complexes containing SNARE proteins is a key phenomenon of exocytosis involving the release of neurotransmitters. When a neurotransmitter is released, acetylcholine binds to an acetylcholine receptor, resulting in muscle contraction by neurotransmission.

A representative example of using this mechanism is Botox. Botox is a non-paralytic method that irreversibly limits muscle contraction and is widely used in cosmetic procedures. Botox irreversibly modifies the SNARE protein to release neurotransmitters. This results in irreversible deformation of the corresponding nerve axons, which ultimately limits muscle contraction. When irreversible deformation by Botox occurs, compensatory action occurs by peripheral nerve branches. Due to this, the applied dose of Botox is inevitably increased. Because Botox is applied in an invasive way, it requires treatment by a medical professional.

Recently, development of peptides or peptide derivatives without side effects while reducing muscle contraction in a non-paralytic manner similar to Botox is being developed. These peptides were used for the purpose of alleviating wrinkles by temporarily blocking the secretion of neurotransmitters such as acetylcholine, which is responsible for the contraction of muscle cells. Receptors that prevent acetylcholine from binding to acetylcholine receptors without limiting the secretion of acetylcholine are also used for the same purpose.

The peptide was only used for the purpose of improving skin-related wrinkles, and it was applied to sports for the purpose of muscle relaxation, management of musculoskeletal disorders, prevention and treatment of muscle pain, alleviation of muscle pain, body shape correction, or cosmetic correction through muscle reduction. there is no

Patent Documents 1 to 10 all contain peptides, but are used only for the purpose of improving skin-related wrinkles.

In the case of a composition for relieving muscle pain containing N-acetylglucosamine and methylsulfonylmethane as active ingredients, it is for the purpose of eliminating inflammation or pain, so it is useful for functional activity of sports or actual muscle relaxation through muscle relaxation. does not participate in the mechanism for Therefore, it is difficult to solve the problem of pain and functional limitation caused by unnecessary muscle contraction.

Patent Document 11 is a composition for topical application containing nanoliposomes in which methylsulfonylmethane and glucosamine are entrapped. It is a composition for substantially eliminating pain, and it is difficult to solve the problems of pain and functional limitation caused by unnecessary muscle contraction.

Patent Documents 12 to 16 suggest new peptides as neurotransmitters, and they are described as acting on the muscle suk, but a composition that can effectively solve the problems of pain and functional limitation caused by unnecessary muscle contraction by using them is not specifically presented.

As such, the conventional peptide composition containing a neurotransmitter is used only for skin improvement such as skin-related wrinkle improvement, and a solution that can effectively solve the problem of pain and functional limitation caused by unnecessary muscle contraction cannot present.

Republic of Korea Patent Publication No. 2004-0021993 ('Patent Document 1') Republic of Korea Patent Publication No. 2018-0113107 ('Patent Document 2') Republic of Korea Patent Publication No. 2018-0028748 ('Patent Document 3') Republic of Korea Patent Publication No. 2017-0139962 ('Patent Document 4') Republic of Korea Patent Publication No. 2016-0122051 ('Patent Document 5') Republic of Korea Patent Publication No. 2004-0083842 ('Patent Document 6') Republic of Korea Patent Publication No. 1865837 ('Patent Document 7') Republic of Korea Patent Publication No. 2006-0030142 ('Patent Document 8') Republic of Korea Patent Publication No. 1912230 ('Patent Document 9') Republic of Korea Patent Publication No. 2020-0049122 ('Patent Document 10') Republic of Korea Patent Publication No. 2017-0113913 ('Patent Document 11') Republic of Korea Patent Publication No. 2006-0115052 ('Patent Document 12') Republic of Korea Patent Publication No. 2015-0002800 ('Patent Document 13') US Patent Publication No. 2013-0323187 ('Patent Document 14') Republic of Korea Patent Publication No. 2012-0104159 ('Patent Document 15') US Patent Publication No. 2013-0323187 ('Patent Document 16')

The present invention is intended to solve the above problems, and is a non-paralytic method for sports for the purpose of muscle relaxation, management of musculoskeletal diseases, prevention and treatment of muscle pain, alleviation of muscle pain, correction of body shape, or cosmetic correction through muscle reduction. An object of the present invention is to provide a composition comprising a peptide or a peptide derivative without side effects while reducing muscle contraction.

The present invention also relates to sports for the purpose of muscle relaxation showing synergistic effects through a mixed composition of peptides or peptide derivatives without side effects while reducing muscle contraction in a non-paralytic manner, management of musculoskeletal disorders, prevention and treatment of muscle pain, muscle pain An object of the present invention is to provide a composition for cosmetic correction through relaxation, body shape correction, or muscle reduction.

In order to solve the above problems, the present invention provides a composition for relieving muscle pain and improving motor function, including a neurotransmitter inhibitor peptide (NIP).

The neurotransmitter inhibitor peptide is at least one or more from the group comprising Docking System Block Peptide (DSBP), which is a peptide that binds to a binding site to which a neurotransmitter binds, and Receptor Block Peptide (RBP), which is a peptide that binds to a neurotransmitter. This can be chosen.

The DSBP comprises at least one of acetyl hexapeptide-3, acetyl hexapeptide-8, pentapeptide-18, palmitoyl hexapeptide-18, palmidoyl hexapeptide-5, and the RBP is pentapeptide-3, tri It may include at least one or more of peptide-3. Specifically, DSBP may be acetyl hexapeptide-3, and RBP may be pentapeptide-3.

The composition for alleviating muscle pain and improving exercise function is as follows

1) Kaempferol, Quercetin, Myricetin, Luteolin, Delphinidin, Cyanidin, Butein, Ellagic acid, Hesperidin (Hesperidin), carrot extract (Magnoliae Cortex), wormwood extract, agaricus mushroom extract, bokbunja product extract, dihydromyricetin, at least one neurotransmission selected from the group comprising hesperidin (Hesperidin) substance inhibitors;

2) adenosine (Adenosine), tomatidine (Solanum Lycopersicum (Tomato) fruit extract), cannabis sativa seed oil (Cannabis Sativa seed oil) at least one selected from the group consisting of a cosmetic improving agent;

3) an activity improving agent selected from the group consisting of magnesium citrate, arnica oil, MSM, glucosamine, and tomatidine (Solanum Lycopersicum (Tomato) fruit extract);

4) Limonene, alpha-isomethylionone, linalool (Spring today), benzyl salicylate, linalool, butylphenylmethylpropional (flower rain), patchouli oil, frankincense oil And at least one stress reliever selected from the group comprising sandalwood oil (Sandalwood oil);

5) a pain reliever selected from the group consisting of ginger oil (6), coriander oil (8), copaiba oil (1), and juniper berry oil (1);

6) Gilkyung extract, decanal, diosmin, perillyl alcohol, suberic acid, geranic acid, ocimene, eugenol, ionone, eucalyptol, chrysanthemum extract, 3,5-dicaffeoyl quinic acid, hydran a muscle strength improving agent selected from the group comprising an active ingredient of genol, 3,5-dicaffeoyl quinic ester;

7) a body shape improving agent selected from the group consisting of hydrogenated phosphatidylcholine, green tea extract, coffee bean extract, and zymophyll root extract (borphyrin);

8) a pain-imparting agent selected from the group consisting of methyl salicylate, menthol, camphor, thymol, capsaicin, nonylate vanilamide, and tocopherol acetate;

At least one or more of them may be added.

In the composition for alleviating muscle pain and improving exercise function according to the present invention, the alleviation of muscle pain includes alleviation of pain in the muscles, and the improvement of the exercise function includes increased muscle activity, decreased muscle fatigue, increased or decreased muscle length, increased flexibility, May include increased strength.

At least one or more of the peptides may be in the form of a W/O/W emulsion.

The present invention also provides at least one of a cream, a spray, an essence, an oil, and a patch comprising the composition for alleviating muscle pain and improving exercise function. Here, the cream is in the form of cream and serum, the spray is in the form of a spray and mist, and the patch is in the form of a patch, a skin adhesion gel, cataplasma, and plasma.

In the present invention, one or two or more non-conflicting components among the above components may be selected and combined.

The present invention provides a composition for relieving muscle pain and improving motor function, including a neurotransmitter inhibitor peptide (Neurotransmitter Inhibitor Peptide, (NIP)). The conventional peptide composition containing a neurotransmitter is used only for skin improvement such as skin-related wrinkle improvement, and could not effectively solve the problem of pain and functional limitation caused by unnecessary muscle contraction, A composition containing a neurotransmitter inhibitor peptide (NIP) according to The advantage is that there are no side effects.

1 is a measurement result of a pressure pain threshold (n=5)] of the trapezius muscle according to Example 1. FIG.
2 is a measurement result of muscle activity (n=5)] measured by electromyography of the trapezius muscle according to Example 1. FIG.
3 is a muscle fatigue analysis (n=5)] measurement results measured by EMG of the upper trapezius muscle according to Example 1. FIG.
4 is a measurement result of the muscle fiber angle analysis of the calf muscle measured by ultrasound according to Example 1: increase in muscle length (n=5)].
5 is a measurement result of increased joint range of motion of dorsiflexion according to Example 1 (n=5).
6 is a measurement result of an increase in muscle strength of an agonist muscle through relaxation of an antagonist muscle according to Example 1 (n=5).
7 is a measurement result of a pressure pain threshold (n=5)] of the calf muscle according to Example 2. FIG.
8 is a measurement result of muscle activity (n=5)] measured by EMG of extensor wrist muscle when holding an object according to Example 2. FIG.
9 is an increase in active joint range of motion of wrist bending according to Example 2 (n=5)] measurement results.
10 is a measurement result of muscle fiber angle analysis of the calf muscle measured by ultrasound according to Example 2: increase in muscle length (n=5)].
11 is a measurement result of muscle activity (n=5) measured by EMG of extensor wrist muscle when holding an object according to Example 3. FIG.
12 is a measurement result of muscle activity (n=5) measured by electromyography of the extensor carpal muscle when the wrist is extended while holding a 1 kg dumbbell according to Example 3. FIG.
13 is a measurement result of increased passive joint range of motion of wrist bending (n=5) according to Example 3;
14 is an analysis of muscle fiber angle of the calf muscle measured by ultrasound according to Example 3: increase in muscle length (n=5).

Hereinafter, embodiments in which those of ordinary skill in the art to which the present invention pertains can easily practice the present invention will be described in detail with reference to the accompanying drawings. However, when it is determined that a detailed description of a related well-known function or configuration may unnecessarily obscure the gist of the present invention in describing the operating principle of the preferred embodiment of the present invention in detail, the detailed description thereof will be omitted.

In addition, the same reference numerals are used throughout the drawings for parts having similar functions and functions. Throughout the specification, when it is said that a part is connected to another part, it includes not only a case in which it is directly connected, but also a case in which it is indirectly connected with another element interposed therebetween. In addition, the inclusion of a certain component does not exclude other components unless otherwise stated, but means that other components may be further included.

In addition, descriptions that limit or add elements may be applied to all inventions unless there are special limitations, and are not limited to specific inventions.

Also, throughout the description and claims of the present application, the singular includes the plural unless otherwise indicated.

Also, throughout the description and claims herein, "or" is intended to include "and" unless stated otherwise. Therefore, "comprising A or B" means all three cases including A, including B, or including A and B.

Also, all numerical ranges include the values at both ends and all intermediate values therebetween, unless expressly stated otherwise.

In the present application, terms such as "comprises", "have" or "include" are intended to designate that the features, numbers, steps, components, parts, or combinations thereof described in the specification exist, but one or more other It should be understood that this does not preclude the possibility of addition or presence of features or numbers, steps, operations, components, parts, or combinations thereof.

When a component is referred to as being “connected” or “connected” to another component, it may be directly connected or connected to the other component, but it is understood that other components may exist in between. it should be On the other hand, when it is said that a certain element is "directly connected" or "directly connected" to another element, it should be understood that the other element does not exist in the middle. Other expressions describing the relationship between elements, such as "between" and "immediately between" or "neighboring to" and "directly adjacent to", etc., should be interpreted similarly.

In addition, unless otherwise defined, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by one of ordinary skill in the art to which the present invention belongs. Terms such as those defined in commonly used dictionaries should be interpreted as having a meaning consistent with the meaning in the context of the related art, and should not be interpreted in an ideal or excessively formal meaning unless explicitly defined in the present application. does not

1 to 14 according to the present invention, AP-8 is acetylhexapeptide-8, PP-3 is pentapeptide-3, Control is a control, Mixed is a mixture thereof, Pre is before treatment, Post is After treatment, 15 min-follow indicates 15 minutes after treatment.

<Example 1>

In this experiment, among the mechanisms regulating neurotransmitters, acetyl hexapeptide-8, a representative substance that inhibits the docking system by inhibiting the formation of SNAREs by neurotransmitters, improves muscle stiffness and improves flexibility. In order to confirm the improvement of muscle fatigue, the tenderness threshold using a pressure algometer and muscle activity and fatigue measured by electromyography are analyzed, and the pennation angle is measured through ultrasound to increase muscle length and joint range of motion. measured.

Acetylhexapeptide-8 used in Example 1 was purchased from Sigma-Aldrich, and a 500ppm solution of acetylhexapeptide-8 was diluted to a concentration of 5% and applied on the skin of the muscle area to be applied.

1 is a measurement result of a pressure pain threshold (n=5) of the trapezius muscle according to Example 1. FIG. A 500 ppm solution of acetylhexapeptide-8 was diluted to a concentration of 5% and applied on the skin of the calf muscle. As a control, 95% aloe solution was applied. At this time, it was confirmed that the pain threshold value of pressure increased when acetylhexapeptide-8 was applied when the time point of pressure at which pain appeared while increasing the pressure in the calf muscle using a pressure statistic was measured. In general, subjects with muscle pain or muscle stiffness have a decreased pain threshold, and as the pressure threshold increases, the improvement of muscle pain is indicated. This is a result value that can confirm the relaxation of the muscle and the improvement of the stiffness of the muscle, and it can also be confirmed that the aggregation of the muscle, which is the cause of the muscle pain, is improved.

FIG. 2 is a measurement result of muscle activity (n=5) measured by electromyography of the upper trapezius muscle according to Example 1. FIG. A 500ppm solution of acetylhexapeptide-8 was diluted to a concentration of 5% and applied on the skin of the trapezius muscle. As a control, 95% aloe solution was applied. Through electromyography, the muscle activity of the trapezius muscle was measured when the shoulder bending motion was performed with a 3 kg dumbbell at an angle of 90 degrees. At this time, a decrease in the activity of the trapezius upper back during shoulder bending motion means a decrease in the muscle tone of the trapezius muscle, and a decrease in the muscle activity of the trapezius upper muscle prevents aggregation of the trapezius muscle and overuse of unnecessary muscles. Efficacy can be confirmed by the example of this experiment.

3 is a measurement result of muscle fatigue analysis (n=5) measured by electromyography of the trapezius muscle according to Example 1. FIG. A 500ppm solution of acetylhexapeptide-8 was diluted to a concentration of 5% and applied on the skin of the trapezius muscle. As a control, 95% aloe solution was applied. The muscle fatigue analysis of the trapezius muscle was performed through electromyography. The muscle fatigue analysis was performed by measuring the EMG for 30 seconds while maintaining 60% of the maximal strength of the trapezius muscle. When acetylhexapeptide-8 was applied, it was possible to confirm the data that the vulnerability to muscle fatigue was improved. 3 shows this before (Pre) and after (Post) application. It can be confirmed that this is effective in improving muscle fatigue. The more easily muscle fatigue occurs, the lower the endurance of the muscle, and more muscle contraction is induced to compensate for this, resulting in muscle pain and fatigue.

4 is a muscle fiber angle analysis of the calf muscle measured by ultrasound according to Example 1: increase in muscle length (n=5) measurement results. A 500 ppm solution of acetylhexapeptide-8 was diluted to a concentration of 5% and applied on the skin of the calf muscle. As a control, 95% aloe solution was applied. At this time, the pennation angle of the muscle was measured through ultrasound. The larger the pennation angle, the shorter and stiffer the muscle length, and the smaller the pennation angle, the greater the muscle length and flexibility. When acetylhexapeptide-8 was applied, it was confirmed that the pennation angle of the calf muscle decreased. It was confirmed that when acetylhexapeptide-8 was applied, the length of the muscle increased and the muscle became flexible. This effect was still observed after 15 minutes after application. The effect of increasing muscle length and flexibility when applied to muscle areas requiring stretching was verified through ultrasound.

5 is a measurement result of increased joint range of motion of dorsiflexion according to Example 1 (n=5). A 500 ppm solution of acetylhexapeptide-8 was diluted to a concentration of 5% and applied on the skin of the calf muscle. As a control, 95% aloe solution was applied. As the length and flexibility of the calf and soleus muscles increase, the range of motion of dorsiflexion of the ankle joint increases. When it is not a problem of the joint itself, the length and flexibility of the muscle are important factors in the range of motion of the joint. When the joint range of motion was measured when actively performing dorsiflexion, when acetylhexapeptide-8 was applied to the calf muscle, the length of the muscle increased and the muscle became flexible. did.

6 is a measurement result of an increase in muscle strength of an agonist muscle through relaxation of an antagonist muscle according to Example 1 (n=5). A 500 ppm solution of acetylhexapeptide-8 was diluted to a concentration of 5% and applied on the skin of the calf muscle. As a control, 95% aloe solution was applied. In order for the muscles of dorsiflexion to generate sufficient strength, the antagonist muscle, the calf muscle, must be relaxed to facilitate the mobilization of the serratus anterior muscle for dorsiflexion. Therefore, the effect of stretching the calf muscle increases the strength of the dorsiflexion. When acetylhexapeptide-8 was applied to the calf muscle, it was confirmed that the muscle strength of dorsiflexion increased due to the effect of muscle stretching. It can be confirmed that applying acetylhexapeptide-8 can be substituted for the effect on muscle stretching.

<Example 2>

In this experiment, there is a method of inhibiting the binding of the neurotransmitter acetylcholine to the acetylcholine receptor in addition to the method of inhibiting the docking system by inhibiting the formation of SNAREs by the neurotransmitter among the mechanisms regulating the neurotransmitter. Pentapeptide-3, a representative substance that inhibits the binding of acetylcholine to the acetylcholine receptor, enhances muscle flexibility, and to compare the efficacy of reducing muscle activity, muscle activity measured by electromyography and ultrasound were used. By measuring the pennation angle, the increase in muscle length and the range of joint motion were measured.

In Example 2, a solution of 2000 ppm concentration of pentapeptide-3 was diluted to a concentration of 1.25% and applied on the skin of the applied muscle area.

7 is a measurement result of a pressure pain threshold (n=5) of the calf muscle according to Example 2. FIG. A 2000 ppm solution of pentapeptide-3 was diluted to a concentration of 1.25% and applied on the skin of the trapezius muscle, and 95% aloe 95% solution was applied as a control. At this time, it was confirmed that the pain threshold value of pressure increased when pentapeptide-3 was applied when the time point at which the pain appeared while increasing the pressure in the calf muscle using a pressure statistic was measured. In general, subjects with muscle pain or muscle stiffness have a decreased pain threshold, and as the pressure threshold increases, the improvement of muscle pain is indicated. This is a result value that can confirm the relaxation of the muscle and the improvement of the stiffness of the muscle, and it can also be confirmed that the aggregation of the muscle, which is the cause of the muscle pain, is improved.

8 is a measurement result of muscle activity (n=5) measured by EMG of extensor wrist muscle when holding an object according to Example 2. FIG. A 2000 ppm solution of pentapeptide-3 was diluted to a concentration of 1.25% and applied on the skin of the extensor wrist muscle, and 95% aloe solution was applied as a control. The muscle activity of the extensor wrist was measured through EMG when the wrist was extended to a predetermined position while holding a weight of 500 g. When wrist extension is performed with the hand held in place, a decrease in the activity of the extensor wrist means a decrease in muscle tone of the extensor wrist, and a decrease in the activity of the extensor wrist prevents aggregation of the extensor wrist and overuse of unnecessary muscles. The effect of giving can be confirmed by the example of this experiment.

9 is a measurement result of an increase in the active joint range of motion of wrist bending (n=5) according to Example 2. FIG. A 2000 ppm solution of pentapeptide-3 was diluted to a concentration of 1.25% and applied on the skin of the extensor wrist muscle, and 95% aloe solution was applied as a control. As the length and flexibility of the extensor wrist and extensor fingers muscles increase, the range of motion of wrist flexion of the wrist joint increases. When it is not a problem of the joint itself, the length and flexibility of the muscle are important factors in the range of motion of the joint. When the joint range of motion was measured when actively performing wrist flexion, when pentapeptide-3 was applied to the extensor wrist, the length of the muscle increased and the muscle became flexible through the increase of the joint range of motion. .

10 is a muscle fiber angle analysis of the calf muscle measured by ultrasound according to Example 2: increase in muscle length (n=5) measurement results. A 2000 ppm solution of pentapeptide-3 was diluted to a concentration of 1.25% and applied on the skin of the calf muscle. As a control, 95% aloe solution was applied. At this time, the pennation angle of the muscle was measured through ultrasound. The larger the pennation angle, the shorter and stiffer the muscle length, and the smaller the pennation angle, the greater the muscle length and flexibility. When pentapeptide-3 was applied, it was confirmed that the pennation angle of the calf muscle decreased. It was confirmed that when pentapeptide-3 was applied, the length of the muscle increased and the muscle became flexible. The effect of increasing muscle length and flexibility when applied to muscle areas requiring stretching was verified through ultrasound.

<Example 3>

In this experiment, among the mechanisms regulating neurotransmitters, the method of inhibiting the docking system by inhibiting the formation of SNARE by the neurotransmitter and the method of inhibiting the binding of the neurotransmitter acetylcholine with the acetylcholine receptor to the acetylcholine receptor were applied at the same time. As a result, a comparative experiment was performed on the efficacy of the method of inhibiting the docking system by inhibiting the formation of SNAREs by the neurotransmitter and the method of inhibiting the binding of the neurotransmitter acetylcholine to the acetylcholine receptor. Pentapeptide-3, a representative substance that inhibits the binding of acetylcholine to the acetylcholine receptor, and acetylhexapeptide-8, a representative substance that inhibits the docking system by inhibiting the formation of SNARE, These two complexes enhance muscle flexibility, and to compare the efficacy of reduction in muscle activity, muscle activity measured by electromyography and pennation angle were measured through ultrasound to measure increase in muscle length and range of motion.

In this example, a 500 ppm solution of acetylhexapeptide-8 was diluted to a concentration of 5% and applied on the skin of the applied muscle area, and a 2000 ppm solution of pentapeptide-3 was diluted to a 1.25% concentration of the applied muscle area. It was applied on the skin, and a solution of 500 ppm concentration of acetylhexapeptide-8 was mixed with a solution of 2.5% concentration and 2000 ppm concentration of pentapeptide-3 with a concentration of 0.625% and applied on the skin of the muscle area to be applied.

11 is a measurement result of muscle activity (n=5) measured by EMG of extensor wrist muscle when holding an object according to Example 3. FIG. A 500 ppm solution of acetylhexapeptide-8 was mixed with a solution of 2.5% concentration and a solution of pentapeptide-3 with a concentration of 2000 ppm, 0.625% concentration, and a 500 ppm solution of acetylhexapeptide-8 was added at 5% concentration and pentapeptide-3 A solution of 2000ppm concentration of 1.25% concentration solution was applied to the wrist extensors, respectively, and 95% solution of aloe was applied as a control. Before, after, and 15 minutes after application, the muscle activity of the extensor carpal muscle was measured through electromyography when the extensor carpal muscle was stretched to a predetermined position while holding a weight of 500 g by hand. When wrist extension is performed with the hand held in place, a decrease in the activity of the extensor wrist means a decrease in muscle tone of the extensor wrist, and a decrease in the activity of the extensor wrist prevents aggregation of the extensor wrist and overuse of unnecessary muscles. The effect of giving can be confirmed by the example of this experiment. The mixed type showed the greatest decrease in muscle activity, followed by acetylhexapeptide-8 and pentapeptide-3.

12 is a measurement result of muscle activity (n=5) measured by electromyography of the extensor carpal muscle when the wrist is extended while holding a 1 kg dumbbell according to Example 3. FIG. A 500 ppm solution of acetylhexapeptide-8 was mixed with a solution of 2.5% concentration and a solution of pentapeptide-3 with a concentration of 2000 ppm, 0.625% concentration, and a 500 ppm solution of acetylhexapeptide-8 was added at 5% concentration and pentapeptide-3 A solution of 2000ppm concentration of 1.25% concentration solution was applied to the wrist extensors, respectively, and 95% solution of aloe was applied as a control. Before, after, and 15 minutes after application, the muscle activity of the extensor wrist was measured through electromyography, respectively, when the wrist was extended to a predetermined position while holding a 1 kg dumbbell by hand. When wrist extension is performed with the hand held in place, a decrease in the activity of the extensor wrist means a decrease in muscle tone of the extensor wrist, and a decrease in the activity of the extensor wrist prevents aggregation of the extensor wrist and overuse of unnecessary muscles. The effect of giving can be confirmed by the example of this experiment. The mixed type showed the greatest decrease in muscle activity, followed by acetylhexapeptide-8 and pentapeptide-3.

13 is a measurement result of increased passive joint range of motion of wrist bending (n=5) according to Example 3; A 500 ppm solution of acetylhexapeptide-8 was mixed with a solution of 2.5% concentration and a solution of pentapeptide-3 with a concentration of 2000 ppm, 0.625% concentration, and a 500 ppm solution of acetylhexapeptide-8 was added at 5% concentration and pentapeptide-3 A solution of 2000ppm concentration of 1.25% concentration solution was applied to the wrist extensors, respectively, and 95% solution of aloe was applied as a control. The range of motion of passive wrist flexion was measured before, after, and 15 minutes after application. As the length and flexibility of the extensor wrist and extensor fingers muscles increase, the range of motion of wrist flexion of the wrist joint increases. When it is not a problem of the joint itself, the length and flexibility of the muscle are important factors in the range of motion of the joint. The mixed type showed the greatest increase in the range of motion, followed by pentapeptide-3 and acetylhexapeptide-8, followed by a decrease.

14 is an analysis of muscle fiber angle of the calf muscle measured by ultrasound according to Example 3: increase in muscle length (n=5) measurement results. A 500 ppm solution of acetylhexapeptide-8 was mixed with a solution of 2.5% concentration and a solution of pentapeptide-3 with a concentration of 2000 ppm, 0.625% concentration, and a 500 ppm solution of acetylhexapeptide-8 was added at 5% concentration and pentapeptide-3 A solution of 2000ppm concentration of 1.25% concentration solution was applied to the wrist extensors, respectively, and 95% solution of aloe was applied as a control. Before, after, and 15 minutes after application, the pennation angle of the muscle was measured through ultrasound. The larger the pennation angle, the shorter and stiffer the muscle length, and the smaller the pennation angle, the greater the muscle length and flexibility. The decrease in the pennation angle can be interpreted as the effect of increasing the length and flexibility of the muscle when it is applied to the muscle area requiring stretching. Acetylhexapeptide-8 showed the greatest decrease in pennation angle, followed by mixed type and pentapeptide-3.

As above has been described in detail a specific part of the content of the present invention, for those of ordinary skill in the art, these specific descriptions are only preferred embodiments, and the scope of the present invention is not limited thereto. It is obvious to those skilled in the art that various changes and modifications can be made within the scope and spirit of the present invention, and it is natural that such variations and modifications fall within the scope of the appended claims.

Claims (12)

A composition for relieving muscle pain and improving motor function, comprising a neurotransmitter inhibitor peptide (Neurotransmitter Inhibitor Peptide, (NIP)). According to claim 1,
The neurotransmitter inhibitor peptide is at least one or more from the group comprising Docking System Block Peptide (DSBP), which is a peptide that binds to a binding site to which a neurotransmitter binds, and Receptor Block Peptide (RBP), which is a peptide that binds to a neurotransmitter. The selected composition for alleviating muscle pain and improving motor function. 3. The method of claim 2,
The DSBP comprises at least one of acetyl hexapeptide-3, acetyl hexapeptide-8, pentapeptide-18, palmitoyl hexapeptide-18, and palmidoyl hexapeptide-52,
The RBP is a composition for alleviating muscle pain and improving exercise function comprising at least one of pentapeptide-3 and tripeptide-3. 4. The method of claim 3,
DSBP is acetyl hexapeptide-8 and RBP is pentapeptide-3. A composition for alleviating muscle pain and improving motor function. According to claim 1,
1) Kaempferol, Quercetin, Myricetin, Luteolin, Delphinidin, Cyanidin, Butein, Ellagic acid, Hesperidin (Hesperidin), carrot extract (Magnoliae Cortex), wormwood extract, agaricus mushroom extract, bokbunja product extract, dihydromyricetin, hesperidin neurotransmission selected from the group consisting of at least one or more substance inhibitors;
2) adenosine (Adenosine), tomatidine (Solanum Lycopersicum (Tomato) fruit extract), cannabis sativa seed oil (Cannabis Sativa seed oil) at least one selected from the group consisting of a cosmetic improving agent;
3) an activity improving agent selected from the group consisting of magnesium citrate, arnica oil, MSM, glucosamine, and tomatidine (Solanum Lycopersicum (Tomato) fruit extract);
4) Limonene, alpha-isomethyl ionone, linalool (Spring today), benzyl salicylate, linalool, butylphenylmethyl propional (flower rain), patchouli oil, frankincense oil And at least one stress reliever selected from the group comprising sandalwood oil (Sandalwood oil);
5) a pain reliever selected from the group consisting of ginger oil (6), coriander oil (8), copaiba oil (1), and juniper berry oil (1);
6) Gilkyung extract, decanal, diosmin, perillyl alcohol, suberic acid, geranic acid, ocimene, eugenol, ionone, eucalyptol, chrysanthemum extract, 3,5-dicaffeoyl quinic acid, hydran a muscle strength improving agent selected from the group comprising the active ingredient of genol, 3,5-dicaffeoyl quinic ester;
7) at least one selected from the group consisting of hydrogenated phosphatidylcholine, green tea extract, coffee bean extract, and zymophyllum root extract (borphyrin);
8) a pain-imparting agent selected from the group consisting of methyl salicylate, menthol, camphor, thymol, capsaicin, nonylate vanilamide, and tocopherol acetate;
A composition for alleviating muscle pain and improving motor function to which at least one of them is added. According to claim 1,
The muscle pain relief includes pain relief for muscles,
The exercise function improvement is a composition for alleviating muscle pain and improving exercise function, including increasing muscle activity, reducing muscle fatigue, increasing or decreasing muscle length, increasing flexibility, and increasing muscle strength. According to claim 1,
At least one of the peptides is in the form of a W/O/W emulsion, a composition for alleviating muscle pain and improving exercise function. A cream comprising the composition for alleviating muscle pain and improving motor function according to any one of claims 1 to 7. A spray comprising the composition for alleviating muscle pain and improving motor function according to any one of claims 1 to 7. An essence comprising the composition for alleviating muscle pain and improving motor function according to any one of claims 1 to 7. An oil comprising the composition for alleviating muscle pain and improving exercise function according to any one of claims 1 to 7. A patch comprising the composition for alleviating muscle pain and improving motor function according to any one of claims 1 to 7.

Images